Navigation Links
Maxygen Announces Hold on MAXY-alpha Development Program
Date:9/21/2007

REDWOOD CITY, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Roche has advised Maxygen, Inc. (Nasdaq: MAXY) that it has voluntarily placed a hold on further clinical development of MAXY-alpha, also known as R7025. MAXY-alpha is a novel interferon-alpha for the treatment of Hepatitis C and Hepatitis B virus infections and is licensed to Roche.

Preliminary observations from a Phase I trial indicate that an unexpected reduction of the pharmacodynamic and pharmacokinetic effects of MAXY-alpha occurred in the majority of subjects who received two doses of MAXY-alpha. In addition, antibodies binding to MAXY-alpha were identified in some subjects. Roche has initiated additional investigational studies in order to assess these results.

"We are all surprised by these unexpected findings," said Russell Howard, Maxygen's chief executive officer. "We don't yet know how this will impact the future timing or advancement of the program. Roche has now started additional work to assess the meaning and significance of these results. We will provide an update once all relevant information is collected and evaluated."

About the Maxygen and Roche Agreement

Maxygen and Roche entered into an agreement in 2003 to develop novel interferon alpha and beta products for a wide range of indications. Roche licensed from Maxygen worldwide commercialization rights to specific novel interferon product candidates for the treatment of Hepatitis C and B virus infections. Maxygen received an initial payment, full research and development funding for work done by Maxygen in the first two years of the collaboration, and milestone payments for the advancement of the MAXY-alpha product candidate. In addition, Maxygen is eligible to receive
'/>"/>

SOURCE Maxygen, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary ... by the Jeffrey Epstein VI Foundation , have shown ... identified for elimination. These aggressive cells are the driver mutations ... topological map of what to look for when examining tumors, ... tumor cells can be extracted from biopsy, it,s very difficult ...
(Date:8/21/2014)... 21, 2014 Ontotext S4 , ... Ontotext . Now the same enterprise hardened ... structured and unstructured data is available to start-ups and ... enterprise technology. Organizations that do not have resources to ... can use S4 since there is no need for ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... is its new technology. Much of the technology for the ... enable it to see farther back in time. As with ... used to benefit humankind in many other industries. The ... to the Hubble Space Telescope. The most powerful space telescope ...
... MILFORD, Mass., April 18, 2012 SeraCare Life Sciences, ... sciences company providing vital products and services to facilitate ... therapeutics, announced that, at a special meeting of shareholders ... agreement with Project Plasma Holdings Corporation and Project Plasma ...
... Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... into a collaboration agreement with the University California, ... acting peptide vaccine candidate to induce an immune ...
Cached Biology Technology:Webb Telescope spinoff technologies already seen in some industries 2Webb Telescope spinoff technologies already seen in some industries 3Webb Telescope spinoff technologies already seen in some industries 4SeraCare Shareholders Approve Acquisition by Linden Capital Partners 2SeraCare Shareholders Approve Acquisition by Linden Capital Partners 3Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 2Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 3Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimer's Research Group at University of California Irvine to Test First in Class Dual Target Vaccine 4
(Date:8/21/2014)... a significant reduction in smog-producing toxins in past ... A new study shows that while the Greater ... the toxins that contribute to smog, the city ... air pollution., Smog, which can cause or aggravate ... bronchitis, is produced by a set of complex ...
(Date:8/21/2014)... but they are the ultimate source of all organic ... dependent on algae, too, to suck up climate-warming carbon ... bottom of the ocean. Now, by using a combination ... showing that viruses infecting those algae are driving the ... else stays essentially the same, and this has important ...
(Date:8/21/2014)... researchers from Beth Israel Deaconess Medical Center (BIDMC ) ... Most Influential Scientific Minds 2014," a comprehensive list ... web resource for science metrics and research performance analysis. ... most influential "are performing and publishing work that their ... science," according to a Thomson Reuters statement. Researchers were ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Viruses take down massive algal blooms, with big implications for climate 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... vaccine for visceral leishmaniasis, a parasitic disease that kills ... issue of ACS Chemical Biology . Spread by ... infects about 500,000 people annually, with the majority of ... , Despite a major research thrust by the World ...
... for speech through in-utero eavesdropping, or is their penchant ... but one that's central to understanding the origins and ... McGill University psychologist believes she's separated out the complicating ... says Dr. Athena Vouloumanos, point to a genetic predilection ...
... there's no picture in this kind of article , ... key role in activating the Epstein Barr Virus in human ... Molecular Biology Laboratory (EMBL) and the Institut de Virologie Moléculaire ... the CNRS, in Grenoble. , Like Sleeping Beauty, the Epstein ...
Cached Biology News:Potential vaccine developed for deadly leishmaniasis disease 2Potential vaccine developed for deadly leishmaniasis disease 3Born with a love of speech 2Born with a love of speech 3Waking a sleeping virus 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Request Info...
Biology Products: